Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Clinical trial NCT05467891 · RECRUITING
Trial details
- NCT number
- NCT05467891
- Sponsor
- Oana Danciu
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-13
- Primary completion
- 2028-08-15
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.